external-link icon-resource-website icon-resource-website

The work of Alfred Health researchers is published in a range of peer reviewed journals.

Search or browse research articles by year, by research area and by publication type.

Publication Details

Associations of alcohol intake, smoking, physical activity and obesity with survival following colorectal cancer diagnosis by stage, anatomic site and tumor molecular subtype

Jayasekara, H., English, D.R., Haydon, A., Hodge, A.M., Lynch, B.M., Rosty, C., Williamson, E.J., Clendenning, M., Southey, M.C., Jenkins, M.A., Room, R., Hopper, J.L., Milne, R.L., Buchanan, D.D., Giles, G.G., MacInnis, R.J.

(2018), Int J Cancer, 238-250

DOI: 10.1002/ijc.31049

The benefits of adding metformin to tamoxifen to protect the endometrium-A randomized placebo-controlled trial

Davis SR, Robinson PJ, Jane F, White S, Brown KA, Piessens S, Edwards A, McNeilage J, Woinarski J, Chipman M, Bell RJ

(2018), Clin Endocrinol, 89(5), 605-612

DOI: 10.1111/cen.13830

Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma

Lewin J, Sayers L, Kee D, Walpole I, Sanelli A, Te Marvelde L, Herschtal A, Spillane J, Gyorki D, Speakman D, Estall V, Donahoe S, Pohl M, Pope K, Chua M, Sandhu S, McArthur GA, McCormack CJ, Henderson M, Hicks RJ, Shackleton M

(2018), Ann Oncol, 29(7), 1569-1574

DOI: 10.1093/annonc/mdy124

Immunotherapy induced pyrexia and the role of PET/CT

McLean L, Soon JA, Haydon A

(2018), Int J Case Rep, 2, 29

DOI: 10.28933/ijcr-2018-06-2901

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, van Akkooi ACJ, Suciu S, Robert C

(2018), N Engl J Med, 378(19), 1789-1801

DOI: 10.1056/NEJMoa1802357

Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy

Adler NR, Wolfe R, McArthur GA, Kelly JW, Haydon A, McLean CA, Mar VJ

(2018), Br J Cancer, 118(10), 1289-1295

DOI: 10.1038/s41416-018-0088-8

Concordance of somatic mutational profile in multiple primary melanomas

Adler NR, McLean CA, Wolfe R, Kelly JW, McArthur GA, Haydon A, Tra T, Cummings N, Mar VJ

(2018), Pigment Cell Melanoma Res, 31(5), 592-603

DOI: 10.1111/pcmr.12702

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

Iveson TJ, Kerr RS, Saunders MP, Cassidy J, Hollander NH, Tabernero J, Haydon A, Glimelius B, Harkin A, Allan K, McQueen J, Scudder C, Boyd KA, Briggs A, Waterston A, Medley L, Wilson C, Ellis R, Essapen S, Dhadda AS, Harrison M, Falk S, Raouf S, Rees C, Olesen RK, Propper D, Bridgewater J, Azzabi A, Farrugia D, Webb A, Cunningham D, Hickish T, Weaver A, Gollins S, Wasan HS, Paul J

(2018), Lancet Oncol, 19(4), 562-578

DOI: 10.1016/S1470-2045(18)30093-7

Immunohistochemistry testing for mismatch repair deficiency in Stage 2 colon cancer: A cohort study of two cancer centres

Grant M, Haydon A, Au L, Wilkins S, Oliva K, Segelov E, Antill Y, Carne P, Ranchod P, Polglase A, Farmer C, Chin M, Wale R, Simpson P, Bell S, Skinner S, McMurrick P, Shapiro J

(2018), Int J Surg, 51, 71-75

DOI: 10.1016/j.ijsu.2018.01.020

Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors

Ameratunga M, Ch»nard-Poirier M, Moreno Candilejo I, Pedregal M, Lui A, Dolling D, Aversa C, Ingles Garces A, Ang JE, Banerji U, Kaye S, Gan H, Doger B, Moreno V, de Bono J, Lopez J

(2018), Eur J Cancer, 89, 56-63

DOI: 10.1016/j.ejca.2017.11.012

Anti-angiogenic therapy for high-grade glioma

Ameratunga M, Pavlakis N, Wheeler H, Grant R, Simes J, Khasraw M

(2018), Cochrane Database Syst Rev, 11, CD008218

DOI: 10.1002/14651858.CD008218.pub4

Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit

Sundar R, Custodio A, Petruckevich A, Ch»nard-Poirier M, Ameratunga M, Collins D, Lim J, Kaye SB, Tunariu N, Banerji U, de Bono J, Lopez J

(2018), Clin Oncol, 30(3), 185-191

DOI: 10.1016/j.clon.2017.11.011

Personalized cancer immunotherapy: Today's challenge and tomorrow's promise

Ameratunga M, Xu W, Lopez J

(2018), J Immunother Precis Oncol, 1, 56-67

DOI: 10.4103/JIPO.JIPO_13_18

CNS cancer immunity cycle and strategies to target this for glioblastoma

Ameratunga M, Coleman N, Welsh L, Saran F, Lopez J

(2018), Oncotarget, 9(32), 22802-22816

DOI: 10.18632/oncotarget.24896

Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials

Sundar R, McVeigh T, Dolling D, Petruckevitch A, Diamantis N, Ang JE, Chenard-Poiri»r M, Collins D, Lim J, Ameratunga M, Khan K, Kaye SB, Banerji U, Lopez J, George AJ, de Bono JS, van der Graaf WT

(2018), Eur J Cancer, 101, 55-61

DOI: 10.1016/j.ejca.2018.06.003

A single-institution prospective evaluation of a neuro-oncology multidisciplinary team meeting

Ameratunga M, Miller D, Ng W, Wada M, Gonzalvo A, Cher L, Gan HK

(2018), J Clin Neurosci, 56, 127-130

DOI: 10.1016/j.jocn.2018.06.032

A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials

Ingles Garces AH, Ang JE, Ameratunga M, Ch»nard-Poirier M, Dolling D, Diamantis N, Seeramreddi S, Sundar R, de Bono J, Lopez J, Banerji U

(2018), Eur J Cancer, 104, 32-38

DOI: 10.1016/j.ejca.2018.08.019

The value of participating in clinical trials: the whole is greater than the sum of its parts

Zalcberg JR, Friedlander M

(2018), Med J Aust, 209(10), 424-425

DOI: 10.5694/mja17.01266

Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre

Moloney M, Faulkner D, Link E, Rischin D, Solomon B, Lim AM, Zalcberg JR, Jefford M, Michael M

(2018), Cancer Chemother Pharmacol, 82(5), 865-876

DOI: 10.1007/s00280-018-3679-4

Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW

Muro K, Cho JY, Bodoky G, Goswami C, Chao Y, Dos Santos LV, Shimada Y, Topuzov E, Van Cutsem E, Tabernero J, Zalcberg J, Chau I, Cascinu S, Cheng R, Hsu Y, Emig M, Orlando M, Fuchs C

(2018), J Gastroenterol Hepatol, 33(4), 814-824

DOI: 10.1111/jgh.14007